Compositions including cannabis and avocado/soybean unsaponifiables and methods of use
The present application relates to compositions comprising avocado/soybean unsaponifiables (“ASU”) and cannabis, and related methods of use. In one embodiment, the cannabis is a cannabis oil extract that is combined with ASU to reduce inflammatory responses and inflammation in humans and animals.
1 . A composition for administering to a subject, wherein the composition comprises a combination of avocado/soybean unsaponifiables in a concentration of 1 to 8.3 μg/mL and cannabinoids in an amount of 25 to 590 ng/ml, based on a total volume of the composition.
2 . The composition of claim 1 , wherein the cannabinoids comprise cannabidiol.
3 . The composition of claim 2 , wherein the source of the cannabinoids is cannabis.
4 . The composition of claim 3 , wherein the source of the cannabidiol is a cannabis extract.
5 . The composition of claim 3 , wherein the source of the cannabidiol is a cannabis oil extract.
6 . The composition of claim 2 , wherein the cannabidiol is synthetic.
7 . The composition of claim 1 , further comprising terpenes.
8 . The composition of claim 1 , further comprising flavonoids.
9 . The composition of claim 1 , formulated for oral administration to an avian subject.
10 . The composition of claim 1 , formulated for oral administration to a mammalian subject.
11 . The composition of claim 10 , wherein the mammalian subject is selected from the group consisting of a human, dog, cat, horse, camel, and cow.
12 . A method of reducing levels of one or more inflammatory mediators comprising: administering to a subject in need thereof a combination of avocado/soybean unsaponifiables and cannabinoids, wherein
(a) the combination of the avocado/soybean unsaponifiables and the cannabinoids are administered in a dosage amount of
(i) the avocado/soybean unsaponifiables are at a dosage of 0.25 mg to 12 mg per kg bodyweight of the subject, and
(ii) the cannabinoids are at a dosage of 0.001 mg to 100 mg per kg bodyweight of the subject.
13 . The method of claim 12 , wherein the cannabinoids comprise cannabidiol.
14 . The method of claim 13 , wherein the source of the cannabidiol is cannabis.
15 . The method of claim 13 , wherein the source of the cannabidiol is a cannabis extract.
16 . The method of claim 13 , wherein the source of the cannabidiol is a cannabis oil extract.
17 . The method of claim 13 , wherein the cannabidiol is synthetic.
18 . The method of claim 12 , wherein the combination further comprises terpenes.
19 . The method of claim 12 , wherein the combination further comprises flavonoids.
20 . The method of claim 12 , wherein the combination is formulated for oral administration to an avian subject.
21 . The method of claim 12 , wherein the one or more inflammatory mediators are selected from the group consisting of interleukin-1β, interleukin-6, and interferon β.
22 . The method of claim 12 , wherein the combination is formulated for oral administration to a mammalian subject.
23 . The method of claim 22 , wherein the mammalian subject is selected from the group consisting of a human, dog, cat, horse, camel, and cow.
24 . The composition of claim 1 , wherein
(a) the subject is a human subject; and
(b) the combination of the avocado/soybean unsaponifiables and the cannabinoids are in the dosage amount of
(i) the avocado/soybean unsaponifiables are a dosage of 0.41 mg to 8.3 mg per kg bodyweight of the human subject, and
(ii) the cannabinoids are a dosage of 2.8 mg to 66.5 mg per kg bodyweight of the human subject.
25 . The composition of claim 24 , formulated for oral administration to the human subject.
26 . The composition of claim 1 , wherein
(a) the subject is a dog subject; and
(b) the combination of the avocado/soybean unsaponifiables and the cannabinoids are in the dosage amount of
(i) the avocado/soybean unsaponifiables are a dosage of 0.25 mg to 8.3 mg per kg bodyweight of the dog subject, and
(ii) the cannabinoids are a dosage of 1.05 mg to 8 mg per kg bodyweight of the human subject.
27 . The method of claim 12 , wherein
(a) the subject is a human subject; and
(b) the combination of the avocado/soybean unsaponifiables and the cannabinoids are administered in the dosage amount of
(i) the avocado/soybean unsaponifiables are a dosage of 0.41 mg to 8.3 mg per kg bodyweight of the human subject, and
(ii) the cannabinoids are a dosage of 2.8 mg to 66.5 mg per kg bodyweight of the human subject.
28 . The method of claim 27 , wherein combination is formulated for oral administration to the human subject.
29 . The method of claim 12 , wherein
(a) the subject is a dog subject; and
(b) the combination of the avocado/soybean unsaponifiables and the cannabinoids are administered in the dosage amount of
(i) the avocado/soybean unsaponifiables are a dosage of 0.25 mg to 8.3 mg per kg bodyweight of the dog subject, and
(ii) the cannabinoids are a dosage of 1.05 mg to 8 mg per kg bodyweight of the human subject.